Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Boston Scientific (BSX) Stock Price & Analysis

1 Followers

BSX Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
CHF 53.92B
Enterprise Value
CHF 74.91B
Total Cash (Recent Filing)
CHF 609.00M
Total Debt (Recent Filing)
CHF 11.95B
Price to Earnings (P/E)
19.0
Beta
0.22
Next Earnings
Feb 03, 2027 (Est.)
EPS Estimate
0.64
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue And Margin Expansion

Strong revenue growth alongside substantial margin expansion indicates improving operating leverage and earnings power. If supported by continued procedure growth and product adoption, these gains can strengthen internal funding capacity, improve returns, and support investment across Boston Scientific’s therapeutic franchises.

Broad-based Product And Market Growth

Growth across neuromodulation and interventional cardiology reduces reliance on any single device category and demonstrates continued clinician adoption in important procedure markets. This breadth supports a more resilient business model, while new approvals and technologies can extend the company’s addressable opportunities.

Solid Balance Sheet And Cash Generation

Moderate leverage, expanding equity, and substantial free cash flow provide financial flexibility for research, product launches, acquisitions, and debt servicing. Although recent cash flow softened, the established cash-generation base gives Boston Scientific capacity to pursue strategic growth without depending solely on external financing.

Bears Say

2027 Growth Challenge

The company’s own outlook points to a difficult near-term growth setup, with several sizeable franchises facing competitive, procedural, and pricing headwinds. This could limit revenue momentum and earnings progression over the next several quarters, even if restructuring savings and later product launches improve the longer-term trajectory.

Margin Pressure From Mix And Pricing

Expected pressure from product mix, China pricing, and ongoing quality and supply-chain investment could prevent strong revenue from translating into proportional profit growth. Lower gross margins would constrain operating leverage and may require efficiency gains or restructuring savings to preserve earnings quality.

Competitive And Launch Execution Risk

Declining EP sales and an extended wait for FARAWAVE Ultra expose Boston Scientific to continued share erosion in an important technology market. The delay increases the period in which competitors can consolidate physician adoption, making eventual recovery more dependent on successful launch execution and clinical uptake.

Boston Scientific News

BSX FAQ

What is Boston Scientific’s market cap?
Boston Scientific’s market cap is CHF53.92B.
When is Boston Scientific’s upcoming earnings report date?
Boston Scientific’s next earnings report is estimated for Feb 03, 2027 (not yet confirmed), which is in 83 days.
How were Boston Scientific’s earnings last quarter?
Boston Scientific released its earnings results on Oct 28, 2026. The company reported CHF0.603 earnings per share for the quarter, beating the consensus estimate of CHF0.6 by CHF0.002.
Is Boston Scientific overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Boston Scientific pay dividends?
Boston Scientific does not currently pay dividends.
What is Boston Scientific’s EPS estimate?
Boston Scientific’s EPS estimate is 0.64.
How many shares outstanding does Boston Scientific have?
Boston Scientific has 1,449,473,300 shares outstanding.
What happened to Boston Scientific’s price movement after its last earnings report?
Boston Scientific reported an EPS of CHF0.603 in its last earnings report, beating expectations of CHF0.6. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Boston Scientific?
Hedge funds hold Boston Scientific shares: the largest hedge-fund position in Boston Scientific is 1,379,577,921 shares, and hedge funds increased their holdings by 25.7M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology